Organon is focusing on expanding the women's health lineup

At the first meeting since its launch, women's health was presented as a vision

New products will be introduced

The demand for unmet diseases related to women's entire life cycle was relatively high.

 

Organon will focus on improving treatment accessibility so that all women can enjoy healthier daily lives." At a press conference held by Organon for the first time since its launch at The Plaza Hotel in Jung-gu, Seoul on the morning of the 2nd, CEO Kim So-eun made the remarks about the company's vision.

 

Kim Soeun, CEO of Oganon Korea

Organon, which spun off from MSD, was officially launched in June last year.

 

Founded in the Netherlands in 1923, Organon was merged with Organon and absorbed into MSD.

 

After about a decade, it was separated from MSD again.

 

Organon, headquartered in New Jersey, USA, has subsidiaries and six manufacturing facilities in more than 60 countries around the world.

 

More than 60 products are supplied to 140 countries.

 

Organon focuses on three areas: women's health, chronic diseases, and biosimilars.

 

Women's health includes women's inherent diseases or diseases that can have a significant impact on women.

 

In chronic diseases, it has about 50 treatments for cardiovascular, respiratory, dermatology, musculoskeletal system, and urinary system.

 

Biosimilars have five products in cooperation with Samsung Bioepis.

 

Fosamax, Atozet, Cozaar, Propecia, etc.

 

are representative.

 

The chronic disease sector accounts for the majority with 70%.

 

CEO Kim said, "We plan to expand our portfolio by identifying women's health needs that are not met in all women's life cycles such as pregnancy and childbirth, and we plan to explore new indications and expand our lineup in chronic diseases." Since its actual launch, Organon has aggressively expanded its portfolio.

 

In June last year, it acquired Alydia Health, a women's health medical device company.

 

Alydia is a company that developed the JADA system, a postpartum bleeding solution.

 

In July, it signed a global license agreement with ObsEva, which developed a premature birth treatment solution.

 

In December, it then acquired Forendo, which has a pipeline of endocrinology-related treatment solutions such as endometrium.

 

CEO Kim said, "We are working on commercializing postpartum bleeding solutions and endocrine treatments outside the United States, and we will make sure that new solutions can be accessed as soon as possible." Organon is preparing for competition of generic for Atozet, which accounts for the largest portion of sales.

 

CEO Kim said, "Generics for Atozet were released last year.

 

We plan to make efforts to expand sales.

 

"We plan to introduce JADA, which was released first in the U.S., in Korea in the near future, and we are looking for new opportunities such as expansion and introduction of indications in other chronic diseases."